Objective. The aim of this study was to assess the mid term effect of proximal bare metal fixation design on renal function in patients undergoing endovascular repair (EVR) of abdominal aortic aneurysm (AAA). Methods. Consecutive EVR patients for AAA from December 1995-2001 were included and grouped to either infrarenal (Group 1) or uncovered suprarenal (Group 2) fixation. Peri-operative renal function and at 6, 12 and 24 months was determined by serum creatinine (sCr mmoll À1 ) and Cockroft-Gault creatinine clearance (CrC mlmin À1 ). Changes in renal function were compared using non-parametric analysis.
Introduction
A specific adaptation designed to improve the suspect long-term durability of early endografts 1, 2 for AAA repair has been the addition of an uncovered bare metal stent to allow supra-renal fixation. 3e5 There are a few potential advantages of this EVR device scheme. Firstly, an enhanced seal may be achieved in native non-aneurysmal supra-renal aortic tissue, reducing the chance of late failure due to device migration and proximal endoleak. 6, 7 This is of particular importance in view of published concern regarding continued infra-renal neck dilatation post-EVR. 8e10 Secondly, these endografts may in fact improve patient eligibility for EVR in cases of adverse neck morphology, since less infra-renal neck is required to generate an adequate seal. 11, 12 The deployment of bare metal stents across the renal artery ostia raises concern regarding subsequent kidney function. Review of the current literature would suggest that this practice is safe at least in the short-term, 6,12e24 but little data exists to confirm this safety in the longer term. The aim of this study was to examine our own EVR experience and assess the consequence of SR-fixation on delayed renal function.
Patients and Methods
One hundred and seventy-nine consecutive patients undergoing EVR for AAA at a single centre over a six-year period (December 1995-December 2001) were identified from a prospectively maintained endovascular database. All case-notes were reviewed and patients alive between 6 months and 2 years post-EVR were recalled.
Patients' sex, age, weight, AAA size (maximal antero-posterior CT projection) and renal function were recorded both pre-and post-operatively (peak value) and at each subsequent follow-up interval of 6, 12 and 24 months. Procedural variables included device type and radiological contrast load. In order to assess any renal effect of fixation-type, the series was divided into two groups depending upon whether they had received infra-renal (IR, Group 1) or suprarenal fixed devices (SR, Group 2). Supra-renal fixation was defined as the presence of a bare-metal stent segment across both renal artery ostia with a proximal seal generated in the native supra-renal aorta. The initial decision as to which device to use, was based primarily on endograft availability at the time of AAA repair, with the IR devices tending to be implanted prior to the availability of the SR devices. In other words, the two study groups were virtually consecutive in chronology with the earlier EVR cases almost exclusively Group 1 (IR) and the latter patients receiving Group 2 devices (SR).
Assessment of renal function was based on the clinically used biochemical marker of serum creatinine (sCr/mmoll À1 ). Paired renal data was available for 135 patients from the entire series at a minimal follow-up time of 6 months. Serum creatinine samples were analysed on an Olympus 2700 multi-channel analyser (Jaffé reaction-based) using the manufacturers supplied reagents (Olympus Instruments, London), providing a between-batch imprecision of less than 2% for each analyte. Creatinine clearance (CrC/mlmin À1 ) values were then derived using the well validated Cockroft-Gault formula 25 with a gender correction factor (multiplication by 0.85) applied for female patients.
Data Analysis
All study information was anonymised and stored within a Microsoft Ò Excel (Microsoft Ltd., Reading, UK) spreadsheet. Relevant data was exported to Minitab Ò Version-13 for Windows (Minitab Inc., PA, USA) software package for statistical and graphical analysis. Unless indicated, median values are quoted for continuous variables. Presentation of renal data is by means of serial box-and-whisker plots.
Observational comparisons with non-continuous data were made using the chi-square test (c 2 ). The one-sample Wilcoxon test was used to compare paired non-parametric continuous variables (i.e. within group) and Mann-Whitney U-test for 2-sample (i.e. between group) non-parametric analysis. A Bonferroni correction factor was applied in both tests for repeated observations. Results were considered statistically significant if p < 0.05. The term 'NS' denotes not statistically significant.
Results
One hundred and seventy-nine patients underwent EVR for AAA within the six-year study period. Eightyseven cases were IR-fixed stents (Group 1) and the remaining 92 patients had SR-fixed devices (Group 2).
Pre-operative status
Group-specific patient demographics, aneurysm size and pre-operative renal function (sCr and CrC) for the entire series are shown in Table 1 . The age range and sex distribution of the study limbs were analogous. The aneurysms of Group 2 were significantly larger than those repaired with infra-renally fixed devices ( p ¼ 0.001).
Thirty-eight patients (Group 1, n ¼ 23; Group 2, n ¼ 15, p ¼ NS) were noted to have occult renal impairment indexed by a serum creatinine > 130 mmoll À1 pre-operatively. No patients were receiving renal replacement therapy (RRT) pre-EVR.
Early outcome & Renal function
Stent deployment was technically successful in all cases with no intra-operative deaths. Endograft type for both groups is summarized in Table 2 . Contrast load during EVR was significantly higher in Group 1 (median 300 ml, range 100e900 ml) as opposed to the later Group 2 cases (median 230 ml, range 110e 800 ml, p ¼ 0.01). The procedural mortality (both inhospital and 30-day) for the entire series was 4.5% (8 of 179 cases). Fixation-specific EVR mortality was not significantly different: 5.7% for Group 1 (5/87; 3 Vanguard & 2 Talent devices) and 3.3% for Group 2 (3/92). Apart from one fatal CVA in a patient receiving a Vanguard device, the documented cause of death in all other cases was myocardial infarction.
No significant difference in sCr was detected post-EVR to either corresponding pre-operative values or between the two groups. Using the Cockroft-Gault formula, group specific CrC values were calculated as a surrogate estimate for GFR in the peri-operative phase. Again, there was no significant difference in CrC either within, or between the groups pre and post-operatively (see Fig. 1 ). Renal replacement therapy (namely CVVH) in the early post-operative period was required by 2 patients, one from each group. In Group 1, a patient with a functionally impaired single kidney (pre-operative sCr 243 mmoll À1 ) became anuric post-EVR with established renal failure reflected by a peak sCr of 461 mmoll À1 . After temporary CVVH in the initial post-operative period, he returned to his pre-operative renal state with 12-month sCr value of 264 mmoll À1 . In Group 2, a patient with pre-existing diabetic nephropathy required RRT post-operatively following the development of acute-on-chronic renal failure (pre-operative sCr 206 mmoll À1 ; post-operative sCr 630 mmoll À1 ). This was precipitated by a peri-operative myocardial infarction with subsequent cardiogenic shock and multi-organ failure. The patient died six days post-EVR.
Inadvertent single renal artery occlusion occurred during stent deployment in two EVR procedures (both Group 2). This insult was reflected in higher post-EVR peak sCr measurements of 125 and 142 mmoll À1 (pre-operative sCr: 91 and 96 mmoll À1 respectively). Nevertheless at 24-month follow-up, no RRT had been necessary in either patient.
Mid-term renal function
Of the 179 cases included in the study, paired renal data was available for 135 patients at a minimal follow-up time of 6 months (Group1, n ¼ 63; Group 2, n ¼ 72). Omitted patients had either died within 6 months of EVR (n ¼ 16), lost to follow-up (n ¼ 11) or were not reviewed nor blood sampled at a correct time interval post-EVR (n ¼ 17).
At 6, 12 and 24-month review, patients of both Groups had no significant elevation in sCr compared to their pre-operative status (see Fig. 2 ). Similarly, there was no difference between the IR and SR groups at each follow-up time interval. Group specific midterm creatinine clearance following EVR is illustrated in Fig. 3 . CrC remained remarkably constant over the 2-year study, regardless of fixation type. Comparison of these GFR estimates between both study limbs at each defined time-point confirmed no significant differences in delayed CrC post-EVR.
There were 3 cases of evolving chronic renal failure post-operatively in the series. The Group 1 case concerned a patient who received a Vanguard device and was noted to have an increasing sCr over the first year's follow-up (pre-op sCr 129 mmoll À1 , 12-month sCr 212 mmoll À1 ) in the absence of other renal disease processes. A renal biopsy was performed which revealed evidence of cholesterol embolization, most likely as a complication of EVR. At last review the patient was clinically well and not requiring RRT. In Group 2, one patient with recognized diabetic nephropathy (pre-EVR sCr 235 mmoll À1 ) was found at first annual follow-up to have a sCr of 318 mmoll À1 . An angiogram was obtained for further investigation, but no evidence of renal artery stenosis was found. The patient is currently under close review by the nephrologists with no RRT. The other patient with a SR device was commenced on haemo-dialysis 3 months post-EVR for progressive renal dysfunction attributed to known polycystic kidneys.
Discussion
The incidence of renal dysfunction post-EVR is reported at approximately 6% and this is notably higher in those patients with pre-operative renal impairment. 26 Although the exact cause of this complication is unclear, implicated factors include radiological contrast-associated nephropathy, renal artery trauma, stent-induced stenosis and aortic neck thromboembolism following vessel instrumentation and manipulation. 12, 20 All of these features are generic to EVR, irrespective of graft configuration.
Since the concept of uncovered supra-renal fixation was first proposed, concern has naturally persisted with respect to its potential additive adverse effect on renal function. Preliminary laboratory studies with animal models suggested that the placement of bare metal stent struts across the renal artery ostia was indeed safe at least in the short-term, 27, 28 and introduction of the practice to man soon followed.
The Lund Group published the earliest report of renal outcome following SR-fixed EVR in humans in 1997. In this study, 18 patients underwent EVR of AAA with deliberate Gianturco Z-stent deployment across one or both renal artery ostia to improve graft durability. At median follow-up of 6 months, all of the 25 stent-covered renal arteries remained patent (imaged by spiral CT and angiography) and no elevation in the cohorts' sCr was observed. 13 Since this seminal paper, several independent groups have addressed the issue of renal function following EVR with uncovered bare metal supra-renal fixation (see Table 3 ). 6,12,14e24,29 Despite varying biochemical and radiological methods for analysis, there is currently no evidence suggesting that these endografts are associated with any clinically significant renal compromise.
In this retrospective study we compared the renal outcome in patients undergoing EVR with devices utilizing either IR or SR fixation by serial measurement of the biochemical markers sCr and Cockroft-Gault formulated CrC. We acknowledge the physiological and analytical limitations of sCr methods, 30, 31 but their measurement permits an appraisal of renal excretory function, which is generally accepted as the best clinical estimate of functional renal mass. 32, 33 Furthermore, it is these indices of kidney function that tend to be routinely used in daily clinical practice.
The two study limbs were comparable in terms of age, sex distribution and pre-operative renal function. No patient in either group required renal replacement therapy pre-operatively. The significantly larger aneurysms of Group 2 reflected both the non-randomized nature of the study and the chronological fact that the first SR device at our institution was not deployed until September 1998, nearly 3 years (and 60 IR devices) after our EVR program had commenced. As a result, Group 2 patients had the benefits of clearer AAA management guidelines, 34 latest device technology and finally the considerable accrued procedural experience of the EVR team i.e. a completed learning curve. The decision regarding the nature of device used (i.e. infrarenal or suprarenal) was dependant on both the aneurysms' morphological suitability determined by contrastenhanced CT scanning and the commercial availability of specific suitable devices at the time of implantation. Patients were not randomized in this study to one specific treatment limb, rather to the most clinically appropriate, cost-effective stent available to them at that particular time.
Although the recently published UK EVAR and Dutch DREAM trials reported a more favourable early survival, 35, 36 this particular series included those patients pre-dating EVAR trial recruitment (commencing early 1999) and also higher-risk individuals who may with hindsight have been better managed conservatively. In spite of this, no deaths were documented as directly due to an acute renal cause. Analysis of sCr and CrC values suggest preserved peri-operative and mid-term renal function, regardless of the presence or absence of uncovered bare metal graft struts across the renal artery ostia. Despite no formalized renal protection policy within the unit, all those patients with 'renal impairment' (abnormally elevated sCr in the absence of RRT) underwent careful intravenous fluid optimization with routine urinary catheterisation and central venous monitoring where appropriate. If possible, the administration of any contrast agent prior to EVR (within 2 weeks) was avoided and the volume used during EVR was restricted to the minimum required. Although it was not the policy of this unit to routinely prescribe putative 'reno-protective' agents such as dopexamine or mannitol, a peri-operative intravenous infusion was commenced if clinically indicated. An additional intra-operative measure taken to minimize renal injury is the angiographic imaging of the renal arteries following partial stent deployment. This permits confirmation of correct device positioning prior to complete release in order to reduce the incidence of renal artery occlusion by the covered segment of the stent. The technique is not completely failsafe and we observed two cases of deployment error in the series (both Zenith devices) with cranial slip after imaging and subsequent single renal artery occlusion. Fortunately, apart from an observed elevation in the sCr of both cases there have been no other clinically significant renal sequelae to this point.
In their series of 315 patients with a mean follow-up of 30.1 months, the Nottingham group report renal outcome following EVR for both ruptured and elective AAA. 17 Pre-EVR renal impairment was defined as sCr > 130 mmoll À1 and/or long-term dialysis. Significant post-operative renal dysfunction was referred to as a 20% increase in sCr from baseline in patients with a 'normal' sCr pre-EVR and additional deterioration in sCr in those with pre-operative renal impairment (n ¼ 69, 21.9%). They concluded that it was only the presence of pre-operative renal failure and not the use of SR fixation that was associated with the permanent post-operative renal dysfunction detected in 9.2% of EVR patients. Although not a formal sub-group analysis, application of the Nottingham renal criteria to our study reveals a comparable rate of pre-operative renal impairment of 21.2% (38 of 179 cases with sCr > 130 mmoll À1 and none receiving long-term dialysis). Post-EVR, we would report a more favourable rate of permanent renal impairment of 4.5% (8 cases) for the entire series. Similarly, group specific renal failure is not significantly different (Fisher exact test): 2.3% for Group 1 (2/87) and 6.5% (6/92) for Group 2. These results are only slightly inferior to the 5% permanent renal dysfunction rate reported by Izzedine et al. following SR-EVR. 19 Much recent interest has focused on the potential application of a low molecular weight protein, cystatin C as a marker of renal function. 37e42 It has been validated by various gold-standard clearance analyses that are inappropriate for routine clinical use, and shown to be superior to sCr measurement in this respect. 43e46 Contrary to sCr, serum cystatin C levels remain unaffected by the physiological variables of sex, muscle mass and dietary intake. 42 Finally and most importantly, significant increases in serum cystatin C have been reported with minimal, currently subclinical mild GFR reduction, allowing a more sensitive and possibly an earlier detection of renal dysfunction than with sCr methods. 42, 47 In view of this, its measurement in a prospective study assessing the potential silent renal injury following SR-EVR is proposed.
In conclusion, this present work adds further supporting biochemical evidence that EVR in the treatment of AAA is indeed safe for the kidneys to mid-term follow-up. Furthermore, this preservation of renal function is independent of proximal fixation designs incorporating uncovered supra-renal fixation. This modification in endograft design to improve both the durability and applicability of EVR in AAA management is not apparently at the expense of mid-term renal function.
